← Ahmad Masri

Papers by Ahmad Masri

Page 3 · newest first

101. The prognostic value of peak oxygen uptake in obstructive hypertrophic cardiomyopathy: a literature review to inform economic model developmentJournal of Medical Economics · 2024
102. SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid CardiomyopathyJournal of the American College of Cardiology · 2024
103. Aficamten for Symptomatic Obstructive Hypertrophic CardiomyopathyNew England Journal of Medicine · 2024
104. Detection of ATTR aggregates in plasma of polyneuropathic ATTR-V30M amyloidosis patients2024
105. Long‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE StudyJournal of the American Heart Association · 2024
106. Safety and Efficacy of Metabolic Modulation With Ninerafaxstat in Patients With Nonobstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2024
107. Stratifying Disease Progression in Patients With Cardiac ATTR AmyloidosisJournal of the American College of Cardiology · 2024
108. Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4Journal of Cardiac Failure · 2024
109. 343 Regional Variability in the Management of Aneurysmal Subarachnoid Hemorrhage for Black Patients: An Analysis of Treatment Patterns, Outcomes, and End-of-life Care.Neurosurgery · 2024
110. Structure-based probe reveals the presence of large transthyretin aggregates in plasma of ATTR amyloidosis patients2024
111. Abstract 1015 Structure-specific peptide probes detect aggregated transthyretin in plasma of transthyretin amyloidosis patientsJournal of Biological Chemistry · 2024
112. The Revolution of Cardiac Myosin Inhibitors in Patients With Hypertrophic CardiomyopathyCanadian Journal of Cardiology · 2024
113. Efficacy and Safety of Acoramidis in Transthyretin Amyloid CardiomyopathyNew England Journal of Medicine · 2024
114. Mavacamten Treatment for Symptomatic Obstructive Hypertrophic CardiomyopathyJACC Heart Failure · 2024
115. EstimATTR: A Simplified, Machine-Learning-Based Tool to Predict the Risk of Wild-Type Transthyretin Amyloid CardiomyopathyJournal of Cardiac Failure · 2023
116. Exercise Capacity in Patients With Obstructive Hypertrophic CardiomyopathyJACC Heart Failure · 2023
117. Long-term effects of mavacamten treatment in obstructive hypertrophic cardiomyopathy (HCM): updated cumulative analysis of the EXPLORER cohort of MAVA-long-term extension (LTE) study up to 120 weeksEuropean Heart Journal · 2023
118. Differentiating Cardiac Troponin Levels During Cardiac Myosin Inhibition or Cardiac Myosin Activation Treatments: Drug Effect or the Canary in the Coal Mine?Current Heart Failure Reports · 2023
119. Eplontersen for Hereditary Transthyretin Amyloidosis With PolyneuropathyJAMA · 2023
120. Medical Therapies to Improve Left Ventricular Outflow Obstruction and Diastolic Function in Hypertrophic CardiomyopathyJACC Advances · 2023
121. Patient-Level Artificial Intelligence–Enhanced Electrocardiography in Hypertrophic CardiomyopathyJACC Advances · 2023
122. Efficacy and safety of dofetilide and sotalol in patients with hypertrophic cardiomyopathyCommunications Medicine · 2023
123. Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3Journal of Cardiac Failure · 2023
124. Imaging cardiac hypertrophy in hypertrophic cardiomyopathy and its differential diagnosisCurrent Opinion in Cardiology · 2023
125. Vigorous Exercise in Patients With Hypertrophic CardiomyopathyJAMA Cardiology · 2023
126. Hospital Procedural Volume and Clinical Outcomes Following Septal Reduction Therapy in Obstructive Hypertrophic CardiomyopathyJournal of the American Heart Association · 2023
127. Efficacy and Safety of Dofetilide and Sotalol in Patients With Hypertrophic Cardiomyopathy2023
128. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2023
129. Liver‐directed drugs for transthyretin‐mediated amyloidosisJournal of the Peripheral Nervous System · 2022
130. Myocardial contrast echocardiography assessment of perfusion abnormalities in hypertrophic cardiomyopathyCardiovascular Ultrasound · 2022
131. Cardiac magnetic resonance for prophylactic implantable-cardioverter defibrillator therapy international study: prognostic value of cardiac magnetic resonance-derived right ventricular parameters substudyEuropean Heart Journal - Cardiovascular Imaging · 2022
132. Myocardial Contrast Echocardiography Assessment of Perfusion Abnormalities in Hypertrophic Cardiomyopathy2022
133. Approach to echocardiography in ARDS patients in the prone position: A systematic reviewEchocardiography · 2022
134. Clinical Clues and Diagnostic Workup of Cardiac AmyloidosisMethodist DeBakey Cardiovascular Journal · 2022
135. Implantable cardioverter‐defibrillators with end stage renal disease: Nationwide inpatient sample database resultsPacing and Clinical Electrophysiology · 2021
136. Perioperative Amiodarone to Prevent Atrial Fibrillation After Septal Myectomy in obstrUctive hypeRtroPHic CardiomyopathyESC Heart Failure · 2021
137. Coronary Artery Calcification and Plaque Characteristics in People Living With HIV: A Systematic Review and Meta‐AnalysisJournal of the American Heart Association · 2021
138. Methodological Rigor and Temporal Trends of Cardiovascular Medicine Meta‐Analyses in Highest‐Impact JournalsJournal of the American Heart Association · 2021
139. Prevalence and Outcomes of p.Val142Ile TTR Amyloidosis Cardiomyopathy: A Systematic ReviewCirculation Genomic and Precision Medicine · 2021
140. Long term mortality and readmissions after transcatheter aortic valve replacementCardiovascular Diagnosis and Therapy · 2021
141. Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studiesEuropean Heart Journal - Quality of Care and Clinical Outcomes · 2021
142. Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature ReviewCardiology and Therapy · 2021
143. Pericardial Tamponade and Other Cardiac Complications in POEMS SyndromeJACC Case Reports · 2021
144. Sinus Arrest and Cardiogenic Shock Precipitated by Immune Checkpoint InhibitorsJACC CardioOncology · 2020
145. Thirty Controversies and Considerations in Hypertrophic CardiomyopathyStructural Heart · 2020
146. Assessment of right ventricular function following left ventricular assist device (LVAD) implantation—The role of speckle‐tracking echocardiography: A meta‐analysisEchocardiography · 2020
147. Protocolized Tracheal and Thoracic Ultrasound for Confirmation of Endotracheal Intubation and Positioning: A Multicenter Observational StudyCritical Care Explorations · 2020
148. Hearts and bones: choose your tracers wiselyEuropean Heart Journal · 2020
149. Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosisEuropean Journal of Heart Failure · 2020
150. TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patientsAmyloid · 2020